New implementation arrangements have been put in place for the TB programs funded through Nigeria’s new TB and TB/HIV grants.
The Global Fund seeks the right balance between risk mitigation and grant implementation in Mali malaria grant
When it recommended a Mali malaria grant for approval recently, the Global Fund’s Grant Approvals Committee (GAC) acknowledged that there are implementation challenges associated with this grant and said that it welcomed the Secretariat’s plans “to identify bottlenecks, and holistically review and harmonize the controls in place with the aim of balancing risk mitigation and effective grant implementation.”
Three countries, three different applications of co-financing in Global Fund grants in sub-Saharan Africa
On 21 December 2018, the Global Fund Board approved 16 country grants worth $229.4 million. It also approved three multi-country grants valued at $24.0 million. The Board was acting on the recommendations of the Technical Review Panel (TRP) and the Grant Approvals Committee (GAC).
Global Fund expresses concern over Benin’s plan to shift funds away from HIV and malaria towards an RSSH funding request
When it reviewed the funding requests from Benin, the Grant Approvals Committee (GAC) and the Technical Review Panel (TRP) expressed serious concerns about what they perceived as gaps in Benin’s HIV and malaria programs – which, they said, were partly due to the decision of the country coordinating mechanism (CCM) to shift some of its allocation towards an RSSH funding request.
The original allocation for Benin was as follows:
Under the new co-financing requirements (previously called “counterpart financing requirements”) adopted by The Global Fund, countries no longer have to meet a minimum threshold expressed as a percentage of the cost of the national programs for HIV, TB, and malaria.
The Global Fund’s new strategy for the period 2017-2022 has a strong focus on the sustainability of investments. This includes supporting countries that are transitioning from Global Fund support to domestic reliance for their disease programs.